Supplementary Data - Tracked from Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure S1. Distribution of BRAF V600E cfDNA mutation fraction across study samples; Supplementary Figure S2. cfDNA-ND patients exhibited higher response rates to dabrafenib and trametinib compared with cfDNA V600E/K patients; Supplementary Table S1. Baseline clinical characteristics; Supplementary Table S2. Correlation between cfDNA mutation fraction, baseline tumor burden (SLD), and LDH; Supplementary Table S3. Association between cfDNA mutation fraction, with baseline covariates; Supplementary Table S4. Association between cfDNA mutation status, with baseline covariates; Supplementary Table S5. cfDNA-ND patients exhibited higher response rates to dabrafenib and trametinib compared with cfDNA V600E/K patients; Supplementary Table S6. cfDNA mutation fraction independently predicts PFS and OS in patients with baseline tumor V600E mutations
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361920343